“We describe the organocatalytic depolymerization of poly(

“We describe the organocatalytic depolymerization of poly(ethylene terephthalate) (PET), using a commercially available guanidine catalyst, 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD). Postconsumer PET IWR-1-endo in vivo beverage bottles were used and processed with 1.0 mol % (0.7 wt %) of TBD

and excess amount of ethylene glycol (EG) at 190 degrees C for 3.5 hours under atmospheric pressure to give bis(2-hydroxyethyl) terephthalate (BHET) in 78% isolated yield. The catalyst efficiency was comparable to other metal acetate/alkoxide catalysts that are commonly used for depolymerization of PET. The BHET content in the glycolysis product was subject to the reagent loading. This catalyst influenced the rate of the depolymerization as well as the effective process temperature. We also demonstrated the recycling of the catalyst and the excess EG for more than 5 cycles. Computational and experimental studies showed that both TBD and EG activate PET through hydrogen bond formation/activation to facilitate this reaction. (C)

2011 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 49: 1273 1281, 2011″
“Apart from inflammatory bowel diseases (IBD), there are several other form of colitis that may resemble macroscopically IBD, entering the differential diagnosis. These forms are represented by infectious colitis, ischemic colitis, pseudomembranous colitis, colitis related to diverticular disease, colitis related to mucosal prolapse, drug colitis, allergic colitis, and microscopic colitis. However, to distinguish between these forms is not always easy, and it frequently requires Staurosporine a strict interrelationship between the pathologist and the gastroenterologist. Here we discuss the more frequent forms CDK inhibitor of non- inflammatory bowel diseases colitides, trying to give useful hints for helping the clinician to better understand the extent to which the pathologist is called to give a definitive response in the differential diagnosis of these entities.”
“Epidermal growth factor receptor (EGER) is attractive target for tumor diagnosis and therapy, as it is specifically and abundantly expressed in tumor

cells. EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). In this study, we investigated whether radioiodinated 4-(3-iodo-phenoxy)-6,7-diethoxy-quinazoline (PRY), which is a candidate EGFR-TK imaging agent for single photon emission computed tomography (SPECT) is able to predict gefitinib sensitivity. We used four NSCLC cell lines-A549 (wild-type EGFR), 111650 (mutant EGER; del E746_A750), 111975 (mutant EGER; L858R, T790M) and 113255 (mutant EGFR; L858R)-and one epidermoid carcinoma cell line, A431 (wild-type EGFR). Cell proliferation assay and Western blotting revealed that A431 and 143255 with high EGFR expression showed high sensitivity to gefitinib.

Comments are closed.